AstraZeneca
-
AstraZeneca inks US$5.3B AI-powered drug discovery deal with China’s CSPC
CSPC will leverage its AI-powered drug discovery platform, which analyzes how target proteins bind with existing compounds to optimize and identify small molecules with the best potential for development.
-
M42 teams up with AstraZeneca , SOPHiA GENETICS to advance liquid biopsy in UAE
Through this collaboration, M42 will incorporate SOPHiA GENETICS’ MSK-ACCESS® technology, powered by SOPHiA DDM™, into its testing services, enabling non-invasive genomic profiling of cancers using a simple blood sample.
-
Abu Dhabi Public Health Centre, AstraZeneca partner to improve COPD care in Abu Dhabi
This initiative also builds on the recommendations of the Abu Dhabi Public Health System Sustainability and Resilience (PHSSR) report, reinforcing the vision of a healthier Abu Dhabi.
-
Revna Biosciences introduces cutting-edge diagnostics in Ghana with AstraZeneca support
Through this partnership, AstraZeneca and Revna Biosciences aim to transform cancer care in Ghana by not only enhancing diagnostic capabilities but also paving the way for targeted therapies tailored to individual patients’ genetic profiles.
-
AstraZeneca invests US$2.5B to expand R&D footprint in China
The new R&D center will prioritize early-stage research and clinical development, enhanced by data science and an AI lab.
-
-
-
-
-
